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ABSTRACT 
Thyroid hormones play an important role in the regulation of body weight, lipid metabolism and insulin resistance. Therefore,  it is predictable 
that thyroid hormones may play an important role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic 
steatohepatitis (NASH). In this study, we reviewed the all current research articles and literatures on the association betwe en hypothyroidism 
(thyroid dysfunction) and NAFLD/NASH. In this study, we conducted a meta-analysis using a comprehensive search of PubMed, MEDLINE, 
EMBASE, Scopus, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trails till April 2019 fo r evaluating the 
relationship between hypothyroidism (thyroid dysfunction) and non-alcoholic fatty liver disease. Sixteen studies were included in the present 
meta-analysis. The present meta-analysis provides strong epidemiological evidence for the relationship between hypothyroidism and NAFLD. 
Both individuals with sub-clinical hypothyroidism and overt hypothyroidism are at higher risk for NAFLD than euthyroid subjects.  
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INTRODUCTION 
Endocrine hormones are generally involved in the regulation 
of body fat, cell metabolism and regulation of energy in the 
human body. Thereby, they play an important role in the 
development of metabolic abnormalities. The thyroid 
hormone significantly involved in energy homeostasis, lipid 
and carbohydrate metabolism, regulation of body weight 
and adipogenesis (1,2). 
Non-alcoholic fatty liver disease (NAFLD) is the most 
common liver disease in worldwide. NAFLD is the most 
common cause of abnormal liver function (3). The growing 
pattern of NAFLD is generally attributed to a global increase 
in the prevalence of obesity and other metabolic disorders, 
such as type II diabetes mellitus, impaired glucose tolerance 
and central obesity. These are the risk factors for NAFLD (4-
7). NAFLD can be categorized into two main categories, non-
alcoholic fatty liver and no-alcoholic steatohepatitis (NASH), 
which is the progressive subtype of NAFLD and can further 
induce liver cirrhosis and hepatocellular carcinoma (8). 
In a clinical background, subclinical hypothyroidism has 
been associated with metabolic disorder, cardiovascular 
mortality and disturbance of lipid metabolism (9,10). In recent 
years, growing body of evidence has lead to speculation on 
the relationship between hypothyroidism and 
NAFLD/NASH. 
ELIGIBLE CRITERIA OF THE STUDIES 
All studies were reviewed and carefully appraised for 
inclusion in this review. All descriptive or analytical cross-
sectional studies, case-control studies, and clinical trials with 
proper methods for assessment of NAFLD and NASH and 
that evaluated thyroid function were included. Additionally, 
only studies that used either ultrasonography or liver biopsy 
for the assessment of NAFLD were included. Studies on 
patients with liver disease other than NAFLD/NASH or on 
NAFLD/NASH in the context of other liver diseases i.e., 
chronic viral hepatitis, liver cirrhosis, acute liver failure, 
hepatocellular carcinoma or drug-induced hepatitis were 
excluded. 
DATA EXTRACTION 
 Initial screening procedure involved the extraction of finally 
selected 16 articles out of 236 randomly found articles 
through electronic search database (Figure 1).  A 
comprehensive search resulted to found articles from 
PubMed, MEDLINE, EMBASE, Scopus, Cochrane Database of 
Systematic Reviews and Cochrane Central Register of 
Controlled Trails. 
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Figure 1: Screening procedure for extraction of articles  
The data from  relevant articles were analyzed to get the 
following information i.e. first author’s name, site of the 
study, year of publication, study design, sample of the study 
(number of the participants), subclinical & overt 
hypothyroidism status and method used to identify and 
verify NAFLD. Relevant data from articles reporting thyroid 
hormone abnormalities and NAFLD/NASH were outlined in 
a Table-1. 
 
Table-1: Characteristics of studies on the relationship between hypothyroidism and NAFLD. 
AUTHERS COUNTRY YEAR 
STUDY 
DESIGN 
STUDY SAMPLE 
(MEAN AGE; FEMALE, 
%) 
STATUS OF 
HYPOTHYROIDISM 
SOURCE OF 
NAFLD 
DIAGNOSIS 
Kaltenbach et 
al.(11) 
Germany 2016 
Cross- 
sectional 
332 individuals 
including 99 NAFLD 
patients (14.1 ± 1.9; 
33.3%) and 233 control 
subjects (13.9 ± 1.8; 
58.8%) 
Subclinical 
hypothyroidism  
(TSH > 4 μU/mL, normal 
FT4) 
Ultrasound 
Bano A et 
al.(12) 
Netherland 2016 Cohort 
9,419 individuals 
(64.7 years; 56.5%) 
Subclinical 
hypothyroidism  
Serum TSH > 4.0 mIU/L 
and normal FT4. Overt 
hypothyroidism was 
defined as serum TSH > 
4.0 mIU/L and FT4 levels 
< 0.85 ng/dl 
Ultrasound 
Gokmen FY et 
al.(13) 
Turkey 2015 
Cross-
sectional 
115 individuals 
including 69 NAFLD 
patients and 46 controls 
(49.9±12.5 years; 
72.2%) 
TSH >4.1mIU/L Ultrasound 
Lee KW et 
al.(14) 
Korea 2015 Cohort 
18,544 individuals 
including 2,348 NAFLD 
patients and 16,196 
controls (39.2±5.9; 
53.3%) 
Subclinical 
hypothyroidism  
(TSH > 4.2 mIU/L, normal 
FT4); overt 
hypothyroidism (TSH > 
4.2 mIU/L, FT4 < 10.97 
ng/dL) 
Ultrasound 
Liu G et al.(15) China 2015 
Cross-
sectional 
2,576 euthyroid subjects  
(45.4±10.3 years) 
TSH >4.78 mIU/L FT3 
3.5–6.5 pmol/L FT4 11.5–
22.7 pmol/L  
 
Ultrasound 
Ludwig U et 
al.(16) 
Germany 2015 
Cross-
sectional 
1,276 individual 
including 349 NAFLD 
and 927 controls 
TSH >34 IU/mL, Total T4 
12.8-20.4 pmol/L, Total 
Ultrasound 
236 Articles were found in electronic search through database 
198 articles excluded after screening of the title, abstract and duplicates 
38 Full-text articles assessed for eligibility 
16 Articles   
22 Articles excluded with reasons 
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(40.7±12.7 years; 
47.2%) 
T3 3.9-6.7 pmol/L 
Parikh P et 
al.(17) 
Western 
India 
2015 
Case– 
control 
800 individuals 
including 500 NAFLD 
patients (44.3 ± 3.2; 
64.6%) and 300 controls 
(41.6 ± 3.89; 66%) 
Subclinical 
hypothyroidism (TSH > 
5.5 IU/mL but <10 
IU/mL) and overt 
hypothyroidism (TSH > 
10 IU/mL) 
Ultrasound 
Posadas-
Romero et 
al.(18) 
Mexico 2014 
Cross- 
sectional 
753 individuals 
including 133 NAFLD 
cases and 620 controls 
(51.9; 63.9%) 
Subclinical 
hypothyroidism  (TSH > 
4.5 mIU/L; normal FT4) 
Enzymatic 
procedures 
Wang et al.(19)  China 2014 
Cross- 
sectional 
806 individuals (56.99 ± 
7.98; 81.3%) 
Subclinical 
hypothyroidism (TSH > 
4.2 μU/mL, FT4: 12–22 
pmol/L) 
Ultrasound 
Eshraghian et 
al.(20) 
Iran 2013 
Cross- 
sectional 
832 individuals 
including 127 NAFLD 
patients (48.2 ± 12.8) 
and 705 controls (36.9 ± 
18.7) (61.3%) 
Subclinical 
hypothyroidism (TSH > 
5.2 mIU/L, normal FT4); 
overt hypothyroidism 
(TSH > 5.2 mIU/L, FT4 < 
11.5 ng/dL) 
Ultrasound 
Pacifico L et 
al.(21) 
Italy 2013 
Cross- 
sectional 
402 individuals (6–16 
years) 144 children with 
NAFLD and 258 controls. 
Subclinical 
hypothyroidism (TSH > 
4.1 mIU/L with normal 
FT4); overt 
hypothyroidism (TSH > 
4.1 mIU/ L with FT4 < 0.7 
ng/dL) 
Ultrasound 
Ittermann et 
al.(22) 
Germany 2012 
Cross- 
sectional 
3,661 individuals 
(48.1±16.1 years; 
47.56%) 
Hypothyroidism was 
defined by increased TSH 
concentrations (3mIU/L) 
and decreased FT3 or 
FT4 concentrations (FT4 
7.7-23.2 pmol/L) 
Ultrasound 
Chung GE et 
al.(23) 
South Korea 2012 
Cross- 
sectional 
4,648 individuals (48.6 ± 
11.8 years; 62.4% ) 
Subclinical 
hypothyroidism (TSH > 
4.1 mIU/L; normal free 
T4 concentration); Overt 
hypothyroidism: FT4 
level < 0.7-1.8 ng/dL 
Ultrasound 
Pagadala et 
al.(24) 
US 2012 
Case– 
control 
663 individuals (50.4; 
56.2%) 
Overt hypothyroidism Histological 
Xu et al.(25)  China 2012 
Case– 
control 
654 individuals 
including 327 subclinical 
hypothyroidism patients 
and 327 controls 
Subclinical 
hypothyroidism (TSH > 
4.5 mIU/L; normal FT4) 
Ultrasound 
Liangpunsakul 
et al.(26)  
USA 2003 
Case– 
control 
616 individuals 
including 174 NAFLD 
and 442 control (49 ± 
13; 59%) 
Overt hypothyroidism 
Enzymatic 
procedures 
 
 
CONCLUSION: 
The present meta-analysis provides strong epidemiological 
evidence for the significant relationship between 
hypothyroidism and NAFLD. Individuals with subclinical 
hypothyroidism and overt hypothyroidism, both are at a 
higher risk for the development of NAFLD than those with 
normal thyroid function. To confirm these results, further 
studies should be made to make a better understanding to 
further strengthen the relationship between NAFLD and 
hypothyroidism. Large-scale and long-term randomized 
controlled trials in various populations must be carried out 
in future studies to deliver more significant evidence.
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